Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Portfolio Pulse from
Structure Therapeutics has initiated dosing in its Phase 2b ACCESS clinical study for GSBR-1290, an oral GLP-1 receptor agonist aimed at treating obesity. The study will evaluate various doses over 36 weeks, with results expected in late 2025.
November 13, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Structure Therapeutics has dosed the first patients in its Phase 2b study for GSBR-1290, targeting obesity. The study will assess multiple doses over 36 weeks, with results anticipated in Q4 2025.
The initiation of the Phase 2b study is a significant milestone for Structure Therapeutics, indicating progress in their drug development pipeline. Positive results could lead to further clinical trials and potential market approval, which would be beneficial for the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100